STRIKE A BALANCE WHEN STARTING AN AED FOR PARTIAL-ONSET (FOCAL) SEIZURES. START WITH VIMPAT®.
STRIKE A BALANCE WHEN STARTING AN AED FOR children with PARTIAL-ONSET (FOCAL) SEIZURES.
Start with VIMPAT® for your pediatric patients (4 years of age and older).
VIMPAT® is indicated for the treatment of partial-onset seizures in patients 4 years of age and older. As the safety of VIMPAT injection in pediatric patients has not been established, VIMPAT injection is indicated for the treatment of partial-onset seizures only in adult patients (17 years of age and older).
SELECT IMPORTANT SAFETY INFORMATION
VIMPAT is associated with important warnings and precautions including suicidal behavior and ideation, dizziness and ataxia, cardiac rhythm and conduction abnormalities, syncope, and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as multi-organ hypersensitivity.
In the adult monotherapy clinical trial, adverse reactions were generally similar to those observed and attributed to drug in adjunctive placebo-controlled trials, with the exception of insomnia (observed at a higher rate of ≥2%). In the adult adjunctive placebo-controlled trials, the most common adverse reactions (≥10% and greater than placebo) were dizziness, headache, nausea, and diplopia. Pediatric adverse reactions are similar to those seen in adult patients.
VIMPAT is a Schedule V controlled substance.
Expanding our commitment TO epilepsy care
for patients with partial-onset seizures.
VIMPAT adult efficacy for monotherapy and adjunctive therapy has been extrapolated for pediatric patients ages 4 and older.
IN THE U.S.Since being approved for adult adjunctive therapy in 2009, UCB has continued to bring VIMPAT to more patients with partial-onset seizures. VIMPAT is now approved for monotherapy and adjunctive therapy in adults and children (ages 4 and older), with >350,000 adult patient exposures in the U.S.1
Approved for adult
Approved for adult
Approved for monotherapy and adjunctive therapy in
CHILDREN ≥4 YEARS OF AGE
YEARS OF COMMITMENT TO ADULT PATIENTS—AND COUNTING
ADULT PATIENT EXPOSURES IN THE U.S.1
Simple dose conversion between formulations.
With VIMPAT, you have administration options. Choose between tablets and oral solution for pediatric and adult patients. Intravenous [IV] injection solution is also available for adult patients. As the safety of VIMPAT injection in pediatric patients has not been established, VIMPAT injection is indicated for the treatment of partial-onset seizures only in adult patients (17 years of age and older).
(Formulations not shown at actual size.)
Patients paid as little
as $20 for a 30-day
supply of VIMPAT.1*
VIMPAT IS COVERED BY MOST COMMERCIAL AND MEDICAID PLANS.
- 95% of commercial and Medicaid patients have formulary access to VIMPAT, and most have unrestricted access1
Eligibility Criteria & Terms: Patients are responsible for a minimum of $20 out-of-pocket expense per 30-day supply. This card will then be applied toward any remaining out-of-pocket expense up to a maximum of $100. Most patients who have commercial prescription insurance are eligible. If you have any questions regarding your eligibility or benefits or if you wish to discontinue your participation, call the VIMPAT Savings Program at 1-888-786-5879 (8:30 AM – 5:30 PM EST, Monday-Friday and 8:30 AM – 2:30 PM EST, Saturday). This savings card is not valid for use by patients who are covered by any federal or state funded healthcare program (including, but not limited to Medicare [Part D and Medigap], Medicaid, any state pharmaceutical assistance program TRICARE, VA, or DoD). Offer good only in the U.S., including Puerto Rico. This card is good for use only with a valid VIMPAT prescription at the time the prescription is filled by the pharmacist and dispensed to the patient. The maximum annual benefit amount is $1300 per calendar year. Void where prohibited by law, taxed, or restricted. This offer cannot be combined with any other promotional offer. UCB, Inc. reserves the right to rescind, revoke, or amend this offer without notice at any time. No cash value. Not eligible for sale, purchase, trade, or counterfeit.
STRIKE A BALANCE FOR YOUR PATIENTS. CHOOSE VIMPAT.
You can request samples through your UCB sales representative or by
calling UCBCares® at 1-844-599-CARE (2273).
- Data on file. UCB, Inc.